StockData
Mesoblast Ltd logo

Mesoblast Ltd (MESO) stock

MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Aug 27, 2026Score 6/30
$11.64−0.27 (-2.27%)

Close on Nov 18, 2026Market cap $1.51BP/E –Yield –

Mesoblast operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

No operating income figures for Mesoblast

Mesoblast has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Mesoblast figures

See a number that looks wrong?